Bonus Material-33_CHEST Board Review 2025 Bronchiectasis-NTM FINAL DAH

Pdf Summary

This comprehensive CHEST Board Review by Dr. Doreen Addrizzo-Harris covers non-CF bronchiectasis (NCFB) and nontuberculous mycobacterial (NTM) lung disease, focusing on pathophysiology, diagnosis, epidemiology, and treatment strategies.<br /><br />NCFB is a chronic syndrome marked by irreversible bronchial dilatation, persistent infection, and inflammation, with many underlying causes including infections, autoimmune disorders, and genetic factors. Diagnosis involves clinical history, imaging (HRCT), microbiologic cultures, and specific tests like immunoglobulin levels, sweat chloride, and ciliary function.<br /><br />Treatment emphasizes airway clearance (nebulized saline, chest physiotherapy), with macrolide antibiotics such as azithromycin recommended for patients with frequent exacerbations due to their anti-inflammatory and anti-infective properties. Inhaled antibiotics (tobramycin, aztreonam, colistin) show benefit especially in pseudomonas infections. New therapies, including neutrophil serine protease inhibitors like brensocatib, have shown promise in reducing exacerbations, with FDA approval expected.<br /><br />NTM lung disease incidence is rising in the U.S., particularly among older adults, often affecting patients with bronchiectasis. Mycobacterium avium complex (MAC) accounts for >80% of cases. Diagnosis requires clinical symptoms, imaging, and microbiologic evidence with multiple positive cultures or bronchoscopy samples. Treatment decisions balance disease severity, patient factors, and risk/benefit, generally using macrolide/ethambutol/rifamycin regimens. Therapy duration extends 12 months post-sputum negativity. Resistant or refractory cases may need clofazimine, inhaled liposomal amikacin (ALIS, FDA approved), or surgery.<br /><br />Mycobacterium abscessus management requires subspecies identification and assessment of inducible macrolide resistance (erm(41) gene). Treatment includes multidrug regimens with amikacin and other antibiotics; surgery may improve outcomes in localized disease.<br /><br />Key points highlight the importance of accurate diagnosis, individualized treatment plans, monitoring, adherence to guidelines, and referral to experienced centers for optimal patient outcomes.

Meta Tag

Concept Non-CF Bronchiectasis

Concept NTM Lung Disease

Concept Mycobacterium abscessus

Concept Diagnostic Evaluation

Concept Airway Clearance

Keywords

non-CF bronchiectasis

NTM lung disease

bronchiectasis

Mycobacterium avium complex

airway clearance

macrolide antibiotics

inhaled antibiotics

brensocatib

amikacin liposomal inhalation suspension

multidrug therapy

Non-CF Bronchiectasis

NTM Lung Disease

Mycobacterium abscessus

Diagnostic Evaluation

Airway Clearance